Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study^*

References

• Baughman RP, Tapson V, McIvor A. The diagnosis and treatment challenges in nosocomial pneumonia. Diagn Microbiol Infect Dis 1999; 33:131–9
   PubMed Web of Science ®Google Scholar
• George DL. Epidemiology of nosocomial pneumonia in intensive care unit patients. Clin Chest Med 1995; 16:29–44
   PubMed Web of Science ®Google Scholar
• Flanders SA, Collard HR, Saint S. Nosocomial pneumonia: state of the science. Am J Infect Control 2006; 34:84–93
   PubMed Web of Science ®Google Scholar
• Shorr AF, Zadeikis N, Jackson WL, . Levofloxacin for treatment of ventilator-associated pneumonia: a subgroup analysis from a randomized trial. Clin Infect Dis 2005; 40 (Suppl 2) S123–9
   PubMed Web of Science ®Google Scholar
• Schmitt DV, Leitner E, Welte T, . Piperacillin/tazobactam vs imipenem/cilastatin in the treatment of nosocomial pneumonia – a double blind prospective multicentre study. Infection 2006; 34:127–34
   PubMed Web of Science ®Google Scholar
• Joshi M, Metzler M, McCarthy M, . Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia. Respir Med 2006; 100:1554–65
   PubMed Web of Science ®Google Scholar
• Fagon JY, Chastre J, Vuagnat A, . Nosocomial pneumonia and mortality among patients in intensive care units. JAMA 1996; 275:866–9
   PubMed Web of Science ®Google Scholar
• Leroy O, Meybeck A, d'Escrivan T, . Hospital-acquired pneumonia in critically ill patients: mortality risk stratification upon onset. Treat Respir Med 2004; 3:123–31
   PubMedGoogle Scholar
• American Thoracic Society & Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388–416
   Google Scholar
• Dietrich ES, Demmler M, Schulgen G, . Nosocomial pneumonia: a cost-of-illness analysis. Infection 2002; 30:61–7
   PubMed Web of Science ®Google Scholar
• Rosenthal VD, Guzman S, Migone O, . The attributable cost and length of hospital stay because of nosocomial pneumonia in intensive care units in 3 hospitals in Argentina: a prospective, matched analysis. Am J Infect Control 2005; 33:157–61
   PubMed Web of Science ®Google Scholar
• Andriesse GI, Verhoef J. Nosocomial pneumonia: rationalizing the approach to empirical therapy. Treat Respir Med 2006; 5:11–30
   PubMedGoogle Scholar
• American Thoracic Society. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventative strategies. Am J Respir Crit Care Med 1996; 153:1711–25
   PubMed Web of Science ®Google Scholar
• Kollef MH, Fraser VJ. Antibiotic resistance in the intensive care unit. Ann Intern Med 2001; 134:298–314
   PubMed Web of Science ®Google Scholar
• Jones ME, Draghi DC, Thornsberry C, . Emerging resistance among bacterial pathogens in the intensive care unit – a European and North American surveillance study (2000–2002). Ann Clin Microbiol Antimicrobial 2004; 3:14
   PubMedGoogle Scholar
• Giantsou E, Liratzopoulos N, Efraimidou E, . Both early-onset and late-onset ventilator-associated pneumonia are caused mainly by potentially multiresistant bacteria. Intensive Care Med 2005; 31:1488–94
   PubMed Web of Science ®Google Scholar
• Rello J, Gallego M, Mariscal D, . The value of routine microbial investigation in ventilator-associated pneumonia. Am J Respir Crit Care Med 1997; 156:196–200
   PubMed Web of Science ®Google Scholar
• Lee SC, Hua CC, Yu TJ, . Risk factors for mortality for nosocomial pneumonia: importance of initial anti-microbial therapy. Int J Clin Pract 2005; 59:39–45
   PubMed Web of Science ®Google Scholar
• Fritsche TR, Stilwell MG, Jones RN. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003). Clin Microbiol Infect 2005; 11:974–84
   PubMed Web of Science ®Google Scholar
• Doribax® (doripenem for injection) package insertRaritan, NJ: Ortho-McNeil Pharmaceutical, Inc., 2008
   Google Scholar
• Chastre J, Wunderink R, Prokocimer P, . Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 2008; 36:1089–96
   PubMed Web of Science ®Google Scholar
• Jones RN, Huynh HK, Biedenbach DJ. Activities of doripenem (S-4661) against drug-resistant clinical pathogens. Antimicrob Agents Chemother 2004; 48:3136–40
   PubMed Web of Science ®Google Scholar
• Jones RN, Sader HS, Fritsche TR. Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli and various β-lactamase resistance mechanisms. Diagn Microbiol Infect Dis 2005; 52:71–4
   PubMed Web of Science ®Google Scholar
• Jones RN, Stillwell MG, Sader HS, . Uniformly enhanced activity of doripenem compared to other carbapenems (imipenem, meropenem) when testing P. aeruginosa isolates: results from three continents [Abstract]. Int J Infect Dis 2006; 10 (Suppl 1) S127–8
   Google Scholar
• Sakyo S, Tomita H, Tanimoto K, . Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa. The high potency of a new carbapenem doripenem. J Antibiot 2006; 59:220–8
   PubMed Web of Science ®Google Scholar
• Mushtaq S, Ge Y, Livermore DM. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob Agents Chemother 2004; 48:3086–92
   PubMed Web of Science ®Google Scholar
• Luna CM, Blanzaco D, Niederman MS, . Resolution of ventilator-associated pneumonia: prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Crit Care Med 2003; 31:676–82
   PubMed Web of Science ®Google Scholar
• Knaus WA, Draper EA, Wagner DP, . APACHE II: a severity of disease classification system. Crit Care Med 1985; 10:818–29
   Web of Science ®Google Scholar
• CLSI. (Clinical and Laboratory Standards Institute). Performance standards for antimicrobial susceptibility testing; Sixteenth Informational SupplementWayne, PA 19087-1898, USA: CLSI, 2006
   Google Scholar
• Merrem® (meropenem for injection) package insertWilmington, DE: AstraZeneca Pharmaceutical, Inc, 2005
   Google Scholar
• Primaxin® (imipenem and cilastatin for injection) package insertWhite House Station, NJ: Merck & Co., Inc., 2005
   Google Scholar
• Alvarez-Lerma F, Insausti-Ordenana J, Jorda-Marcos R, . Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial. Intensive Care Med 2001; 27:493–502
   PubMed Web of Science ®Google Scholar
• Cochran WG. Some methods for strengthening the common χ2-tests. Biometrics 1954; 10:417–51
   Web of Science ®Google Scholar
• Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22:719–48
   PubMed Web of Science ®Google Scholar
• Karlowsky JA, Jones ME, Thornsberry C, . Stable antimicrobial susceptibility rates for clinical isolates of Pseudomonas aeruginosa from the 2001–2003 tracking resistance in the United States today surveillance studies. Clin Infect Dis 2005; 40 (Suppl 2) S89–98
   PubMed Web of Science ®Google Scholar
• Zosyn® (piperacillin tazobactam) package insertPhiladelphia, PA: Wyeth Pharmaceutical, Inc, 2007
   Google Scholar
• Rhomberg PR, Fritsche TR, Sader HS, . Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Information Collection Program (USA). Diagn Microbiol Infect Dis 2006; 56:57–62
   PubMed Web of Science ®Google Scholar
• Horiuchi M, Kimura M, Tokumura M, . Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with β-lactam antibiotics. Toxicology 2006; 222:114–24
   PubMed Web of Science ®Google Scholar
• Lucasti C, Jasovich A, Umeh O, . Treatment of complicated intra-abdominal infections: doripenem versus meropenem. A prospective multicenter, double-blind, randomized, phase 3 study comparing efficacy and safety demonstrates non-inferiority of intravenous doripenem to meropenem in adults with complicated intra-abdominal infections. Clin Ther 2008; 30:105–13
   Web of Science ®Google Scholar
• Naber K, Redman R, Kotey P, . Intravenous therapy with doripenem versus levofloxacin with an option for oral step-down therapy in the treatment of complicated urinary tract infection and pyelonephritis. Presented at: 17th European Congress of Clinical Microbiology and Infectious DiseasesMunich, GermanyMarch 31–April 3, 2007. Poster P833
   Google Scholar